Jan 09, 2018
While President Donald Trump's Health and Human Services (HHS) nominee Alex Azar--a former pharma executive--spent most of his Senate confirmation hearing on Tuesday ducking and dodging pointed questions about his long history of "price gouging," Sen. Elizabeth Warren (D-Mass.) decided to call Azar out on his support for gutting Medicaid and turning the program into a block grant.
After Azar suggested he supports block granting Medicaid as a "concept to look at" but refused to say whether he would move in that direction if confirmed, Warren said, "Mr. Azar, you can own up to the fact that you want to cut Medicaid and gut the Affordable Care Act, like every other member of the Trump administration."
"But you want to smile and pretend otherwise until you get the job," Warren added. "No one should be fooled."
\u201cAlex Azar wants to smile and pretend he\u2019s different from @realDonaldTrump\u2019s last HHS Secretary, Tom Price. But I don\u2019t see the difference. They both want to tear down Medicaid. #SayNoToAzar\u201d— Elizabeth Warren (@Elizabeth Warren) 1515522083
As recently as February of last year, Azar--who worked as an executive for the pharma giant Eli Lilly for a decade--said he believes there is "a lot to commend a block grant approach."
"At a time when the U.S. is facing a nationwide crisis of access to affordable medicines, the top official in charge of healthcare should not be a former pharmaceutical company executive with a history of making lifesaving medicines unaffordable."
-- Public Citizen
In an analysis published in 2016, the Center on Budget and Policy Priorities concluded that the "approach" hinted at by Azar would "institute deep cuts to federal funding for state Medicaid programs and threaten benefits for tens of millions of low-income families, senior citizens, and people with disabilities."
Consumer groups and progressive lawmakers have repeatedly raised alarm about Azar's right-wing healthcare views and his record of drastically hiking drug prices since he was picked by Trump to replace ousted HHS Secretary and private jet enthusiast Tom Price last November.
"At a time when the U.S. is facing a nationwide crisis of access to affordable medicines, the top official in charge of healthcare should not be a former pharmaceutical company executive with a history of making lifesaving medicines unaffordable," Public Citizen said in a statement ahead of Azar's appearance before the Senate Finance Committee on Tuesday.
During one of the more tense exchanges of the hearing, Sen. Ron Wyden (D-Ore.)--with a chart showing how quickly the ADHD drug Strattera skyrocketed on Azar's watch strategically positioned behind him--asked Azar if he "ever lower[ed] the price of a Lilly drug sold in the United States."
Azar refused to answer the question directly, saying, "Drug prices are too high."
"I don't know that there is any drug price of a branded product that has ever gone down from any company on any drug in the United States because every incentive in this system is toward higher prices," Azar added.
Why Your Ongoing Support Is Essential
Donald Trump’s attacks on democracy, justice, and a free press are escalating — putting everything we stand for at risk. We believe a better world is possible, but we can’t get there without your support. Common Dreams stands apart. We answer only to you — our readers, activists, and changemakers — not to billionaires or corporations. Our independence allows us to cover the vital stories that others won’t, spotlighting movements for peace, equality, and human rights. Right now, our work faces unprecedented challenges. Misinformation is spreading, journalists are under attack, and financial pressures are mounting. As a reader-supported, nonprofit newsroom, your support is crucial to keep this journalism alive. Whatever you can give — $10, $25, or $100 — helps us stay strong and responsive when the world needs us most. Together, we’ll continue to build the independent, courageous journalism our movement relies on. Thank you for being part of this community. |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
While President Donald Trump's Health and Human Services (HHS) nominee Alex Azar--a former pharma executive--spent most of his Senate confirmation hearing on Tuesday ducking and dodging pointed questions about his long history of "price gouging," Sen. Elizabeth Warren (D-Mass.) decided to call Azar out on his support for gutting Medicaid and turning the program into a block grant.
After Azar suggested he supports block granting Medicaid as a "concept to look at" but refused to say whether he would move in that direction if confirmed, Warren said, "Mr. Azar, you can own up to the fact that you want to cut Medicaid and gut the Affordable Care Act, like every other member of the Trump administration."
"But you want to smile and pretend otherwise until you get the job," Warren added. "No one should be fooled."
\u201cAlex Azar wants to smile and pretend he\u2019s different from @realDonaldTrump\u2019s last HHS Secretary, Tom Price. But I don\u2019t see the difference. They both want to tear down Medicaid. #SayNoToAzar\u201d— Elizabeth Warren (@Elizabeth Warren) 1515522083
As recently as February of last year, Azar--who worked as an executive for the pharma giant Eli Lilly for a decade--said he believes there is "a lot to commend a block grant approach."
"At a time when the U.S. is facing a nationwide crisis of access to affordable medicines, the top official in charge of healthcare should not be a former pharmaceutical company executive with a history of making lifesaving medicines unaffordable."
-- Public Citizen
In an analysis published in 2016, the Center on Budget and Policy Priorities concluded that the "approach" hinted at by Azar would "institute deep cuts to federal funding for state Medicaid programs and threaten benefits for tens of millions of low-income families, senior citizens, and people with disabilities."
Consumer groups and progressive lawmakers have repeatedly raised alarm about Azar's right-wing healthcare views and his record of drastically hiking drug prices since he was picked by Trump to replace ousted HHS Secretary and private jet enthusiast Tom Price last November.
"At a time when the U.S. is facing a nationwide crisis of access to affordable medicines, the top official in charge of healthcare should not be a former pharmaceutical company executive with a history of making lifesaving medicines unaffordable," Public Citizen said in a statement ahead of Azar's appearance before the Senate Finance Committee on Tuesday.
During one of the more tense exchanges of the hearing, Sen. Ron Wyden (D-Ore.)--with a chart showing how quickly the ADHD drug Strattera skyrocketed on Azar's watch strategically positioned behind him--asked Azar if he "ever lower[ed] the price of a Lilly drug sold in the United States."
Azar refused to answer the question directly, saying, "Drug prices are too high."
"I don't know that there is any drug price of a branded product that has ever gone down from any company on any drug in the United States because every incentive in this system is toward higher prices," Azar added.
While President Donald Trump's Health and Human Services (HHS) nominee Alex Azar--a former pharma executive--spent most of his Senate confirmation hearing on Tuesday ducking and dodging pointed questions about his long history of "price gouging," Sen. Elizabeth Warren (D-Mass.) decided to call Azar out on his support for gutting Medicaid and turning the program into a block grant.
After Azar suggested he supports block granting Medicaid as a "concept to look at" but refused to say whether he would move in that direction if confirmed, Warren said, "Mr. Azar, you can own up to the fact that you want to cut Medicaid and gut the Affordable Care Act, like every other member of the Trump administration."
"But you want to smile and pretend otherwise until you get the job," Warren added. "No one should be fooled."
\u201cAlex Azar wants to smile and pretend he\u2019s different from @realDonaldTrump\u2019s last HHS Secretary, Tom Price. But I don\u2019t see the difference. They both want to tear down Medicaid. #SayNoToAzar\u201d— Elizabeth Warren (@Elizabeth Warren) 1515522083
As recently as February of last year, Azar--who worked as an executive for the pharma giant Eli Lilly for a decade--said he believes there is "a lot to commend a block grant approach."
"At a time when the U.S. is facing a nationwide crisis of access to affordable medicines, the top official in charge of healthcare should not be a former pharmaceutical company executive with a history of making lifesaving medicines unaffordable."
-- Public Citizen
In an analysis published in 2016, the Center on Budget and Policy Priorities concluded that the "approach" hinted at by Azar would "institute deep cuts to federal funding for state Medicaid programs and threaten benefits for tens of millions of low-income families, senior citizens, and people with disabilities."
Consumer groups and progressive lawmakers have repeatedly raised alarm about Azar's right-wing healthcare views and his record of drastically hiking drug prices since he was picked by Trump to replace ousted HHS Secretary and private jet enthusiast Tom Price last November.
"At a time when the U.S. is facing a nationwide crisis of access to affordable medicines, the top official in charge of healthcare should not be a former pharmaceutical company executive with a history of making lifesaving medicines unaffordable," Public Citizen said in a statement ahead of Azar's appearance before the Senate Finance Committee on Tuesday.
During one of the more tense exchanges of the hearing, Sen. Ron Wyden (D-Ore.)--with a chart showing how quickly the ADHD drug Strattera skyrocketed on Azar's watch strategically positioned behind him--asked Azar if he "ever lower[ed] the price of a Lilly drug sold in the United States."
Azar refused to answer the question directly, saying, "Drug prices are too high."
"I don't know that there is any drug price of a branded product that has ever gone down from any company on any drug in the United States because every incentive in this system is toward higher prices," Azar added.
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.